Published in BMC Nephrol on July 12, 2013
Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases? Front Immunol (2013) 0.95
TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. Front Immunol (2014) 0.87
The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients. BMC Nephrol (2014) 0.81
A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation. Clin J Am Soc Nephrol (2014) 0.81
Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Clin J Am Soc Nephrol (2016) 0.75
TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner. Am J Transl Res (2016) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol (2005) 4.92
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int (2002) 4.29
Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol (2008) 3.15
Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol (2004) 3.00
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol (2008) 2.96
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int (2000) 2.72
Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant (2005) 2.40
Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol (2008) 2.26
Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant (1996) 2.21
Mechanisms of rejection: current perspectives. Transplantation (2012) 2.19
Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol (2006) 2.00
TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev (2003) 1.96
Cardiovascular mortality in end-stage renal disease. Am J Med Sci (2003) 1.88
TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem (2003) 1.81
Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol (2011) 1.77
TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev (2011) 1.70
Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl (1989) 1.66
Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol (2001) 1.54
The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol (2008) 1.43
Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int (2006) 1.34
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.25
Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.22
The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail (2011) 1.20
Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13
Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. J Immunol (2009) 1.05
Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis (2011) 0.99
Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int (2000) 0.99
Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev (2009) 0.95
Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Am J Nephrol (2009) 0.93
Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis (2010) 0.87
Kidney transplantation improves arterial function measured by pulse wave analysis and endothelium-independent dilatation in uraemic patients despite deterioration of glucose metabolism. Nephrol Dial Transplant (2010) 0.86
Fetuin-A, inflammation, and coronary artery calcification in hemodialysis patients. Indian J Nephrol (2011) 0.86
Progression of coronary artery calcification in renal transplant recipients. Nephrol Dial Transplant (2011) 0.86
The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. Ren Fail (2012) 0.83
Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol (2007) 3.06
Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant (2010) 2.94
Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int (2013) 2.74
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Can neutrophil/lymphocyte ratio predict recurrence of non-valvular atrial fibrillation after cardioversion? Anadolu Kardiyol Derg (2012) 2.14
Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. Int Urol Nephrol (2012) 2.12
The relationship between uric acid and erectile dysfunction in hypertensive subjects. Blood Press (2014) 2.01
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant (2013) 1.88
Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis. Eur J Gastroenterol Hepatol (2013) 1.74
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant (2010) 1.65
Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrol Dial Transplant (2013) 1.62
Thrombotic thrombocytopenic purpura secondary to ABO group incompatible blood transfusion in a patient after cardiac surgery. Indian J Crit Care Med (2013) 1.59
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab (2014) 1.57
The relationship between neutrophil-to-lymphocyte ratio and vascular calcification in end-stage renal disease patients. Hemodial Int (2013) 1.55
Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant (2006) 1.53
Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant (2011) 1.50
The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients. Ren Fail (2012) 1.48
Negative outcome studies in end-stage renal disease: how dark are the storm clouds? Nephrol Dial Transplant (2007) 1.44
Management of right heart thrombi associated with acute pulmonary embolism: a retrospective, single-center experience. Anadolu Kardiyol Derg (2013) 1.43
Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: a randomized double-blind placebo-controlled trial. Hemodial Int (2013) 1.40
A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol (2011) 1.40
Acute myocardial infarction triggered by bee sting. Emerg Med Australas (2013) 1.39
Ankylosing spondylitis with mycetoma case treated with oral itraconazole. Rheumatol Int (2009) 1.39
Homocysteine levels in patients with masked hypertension. Anadolu Kardiyol Derg (2014) 1.38
The protein science of biosimilars. Nephrol Dial Transplant (2006) 1.36
Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int (2013) 1.35
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant (2010) 1.34
Blue rubber bleb nevus syndrome: successful treatment with sirolimus. Pediatrics (2012) 1.31
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant (2013) 1.28
Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol (2008) 1.27
The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail (2011) 1.20
Pulmonary hypertension in CKD. Am J Kidney Dis (2012) 1.19
Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif (2009) 1.19
Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. Nephrol Dial Transplant (2006) 1.16
Neutrophil lymphocyte ratio as a predictor of stroke. J Stroke Cerebrovasc Dis (2013) 1.13
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant (2010) 1.11
Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrol Dial Transplant (2008) 1.11
Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif (2009) 1.10
Mechanisms and consequences of salt sensitivity and dietary salt intake. Curr Opin Nephrol Hypertens (2011) 1.09
Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol (2012) 1.09
Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.09
Causes and consequences of increased arterial stiffness in chronic kidney disease patients. Kidney Blood Press Res (2007) 1.06
IL-33 exacerbates acute kidney injury. J Am Soc Nephrol (2011) 1.05
Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease. Am J Med Sci (2014) 1.05
Lipid, blood pressure and kidney update 2013. Int Urol Nephrol (2014) 1.05
Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant (2004) 1.05
Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation (2006) 1.03
A rare human infection of Raoultella ornithinolytica in a diabetic foot lesion. Ann Saudi Med (2011) 1.02
Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol (2012) 1.02
Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int (2004) 1.01
Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int Urol Nephrol (2011) 1.01
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol (2011) 1.01
Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med (2013) 1.01
Anemia after renal transplantation. Am J Kidney Dis (2006) 1.01
Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. Nephrol Dial Transplant (2010) 0.99
The effect of diabetes mellitus on the P-wave dispersion. Circ J (2007) 0.99
Evaluation of risk factors and seroprevalence of hepatitis B and C in diabetic patients in Kutahya, Turkey. J Investig Med (2008) 0.98
Serum vitamin D levels are independently associated with severity of coronary artery disease. J Investig Med (2012) 0.97
Methods and potential biomarkers for the evaluation of endothelial dysfunction in chronic kidney disease: a critical approach. J Am Soc Hypertens (2010) 0.96
Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif (2010) 0.96
Delirium following acute myocardial infarction: incidence, clinical profiles, and predictors. Perspect Psychiatr Care (2010) 0.96
Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. J Investig Med (2011) 0.95
Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) (2012) 0.95
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol (2008) 0.95
Arrhythmias in hemodialysis patients. J Nephrol (2009) 0.94
Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant (2013) 0.93
COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant (2012) 0.92
Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol (2010) 0.92
Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol (2011) 0.92
The relationship between epicardial adipose tissue and malnutrition, inflammation, atherosclerosis/calcification syndrome in ESRD patients. Clin J Am Soc Nephrol (2011) 0.92